The Vienna General Hospital, usually abbreviated to AKH, is the general hospital of the city of Vienna, Austria. It is also the city's university hospital, and the site of the Medical University of Vienna. It is Europe's fifth largest hospital, both by number of employees and bed capacity.

There are 2,200 beds in AKH - Medizinische Universität Wien.

During the past decade, AKH - Medizinische Universität Wien conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 8 clinical trials were completed, i.e. on average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 7 clinical trials were completed. i.e. 140% of trials that started reached the finish line.

Out of the total clinical trials conducted in "AKH - Medizinische Universität Wien" #1 sponsor was "Pfizer" with 4 trials, followed by "Galapagos NV" with 3 trials sponsored, "Arena Pharmaceuticals" with 2 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "AKH - Medizinische Universität Wien" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Cooperative Trials Group for Neuro-Oncology (COGNO)" with 1 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "AKH - Medizinische Universität Wien" are "Ulcerative Colitis" (5 trials), "Crohn's Disease" (2 trials), "Influenza A" (2 trials), "Arthritis, Rheumatoid" (1 trials) and "Astrocytoma, Grade III" (1 trials). Many other conditions were trialed in "AKH - Medizinische Universität Wien" in a lesser frequency.

Most popular intervention types in "AKH - Medizinische Universität Wien" are "Drug" (15 trials), "Other" (3 trials), "Radiation" (2 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Filgotinib" (4 trials), "Etrasimod" (3 trials), "Pimodivir 600 mg" (2 trials) and "SOC Treatment" (2 trials). Other intervention names were less common.

The vast majority of trials in "AKH - Medizinische Universität Wien" are 16 trials for "All" genders.

Currently, there are NaN active trials in "AKH - Medizinische Universität Wien". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 8 completed trials in AKH - Medizinische Universität Wien, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in AKH - Medizinische Universität Wien, 1 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".